Navigation Links
Irritable bowel syndrome can have genetic causes
Date:12/10/2008

Irritations of the bowel can have genetic causes. Researchers at the Institute of Human Genetics at Heidelberg University Hospital have discovered this correlation. The causes of what is known as irritable bowel syndrome (IBS), one of the most common disorders of the gastrointestinal tract, are considered unclear making diagnosis and treatment extremely difficult. The results from Heidelberg, which were published in the prestigious jour-nal "Human Molecular Genetics", improve the outlook for an effective medication against a disease that is frequently played down as a func-tional disorder.

In Germany, approximately five million people are affected by IBS, women about twice as often as men. But only around 20 percent of these people even consult a physician. Many patients suffer from constipation, others from severe diarrhea, or a combination of both. The illness affects the general condition and quality of life of these patients and often lasts for months or even years.

Modified receptors lead to overstimulation of the bowel

Serotonin plays an important role in the complex processes in the diges-tive tract just as it affects sleep, mood, and blood pressure. Various types of receptors are located in the intestine, to which serotonin attaches according to the lock and key principle and thus transmits cellular signals.

"We have determined that patients who suffer from irritable bowel syn-drome with diarrhea show a higher frequency of certain mutations ", ex-plains Dr. Beate Niesler, who investigates the genetic causes of complex diseases with her team in the Department of Human Molecular Genetics (Director: Prof. Gudrun Rappold) at the Heidelberg Institute of Human Genetics. These mutations appear to cause changes in the composition or number of receptors on the cell surface. "The signal transduction in the digestive tract may be disturbed and this may lead to overstimulation of the intestine. Resulting disturbances in fluid balance could explain the occurrence of diarrhea", says Johannes Kapeller, a PhD student in the team.

Medication blocks serotonin receptors

The serotonin receptor blocker Alosetron is only approved in the US where it is effectively used in the treatment of women suffering from diarrhea-predominant IBS, but can only be prescribed with strict limitations due to its side effects. Alosetron inhibits the serotonin receptors in the intestinal tract and thus slows the movement of the bowels.

"Currently, patients with irritable bowel syndrome are treated on a trial and error basis"", explains Dr. Beate Niesler. The Heidelberg data could contribute to development and prescription of specific medications for certain genetic mutations in patients.

Correlation with depression and pain

Research of the serotonin system shows interesting correlations sero-tonin receptors are located on neural transduction pathways involved in pain perception and influence them which could explain why patients with irritable bowel syndrome often complain of severe pain although no pathological changes such as infections or tumors are present. It has also been noted that persons with modified receptors suffer more frequently from depression.


'/>"/>

Contact: Dr. Annette Tuffs
annette.tuffs@med.uni-heidelberg.de
0049-622-156-4536
University Hospital Heidelberg
Source:Eurekalert

Related biology news :

1. Is yakult helpful in the treatment of irritable bowel syndrome?
2. Clinical studies show REMICADE reduces incidence of bowel surgeries in ulcerative colitis patients
3. Scientists successfully treat new mouse model of inflammatory bowel disease
4. New genes found for inflammatory bowel disease in children
5. Scientists link fragile X tremor/ataxia syndrome to binding protein in RNA
6. Researchers identify proteins involved in new neurodegenerative syndrome
7. Restless legs syndrome affects nearly 2 percent of US/UK children
8. Obesity-related hormone is higher in children with Down syndrome
9. Rare cancer-causing syndrome found, for the first time, in Singapore
10. Effective ADHD treatment found for children with fragile X syndrome
11. Study suggests new way to screen infants for fetal alcohol syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Research and Markets has announced the addition ... to their offering. The report ... to grow at a CAGR of 12.28% during the period 2016-2020. ... in-depth market analysis with inputs from industry experts. The report covers ... The report also includes a discussion of the key vendors operating ...
(Date:6/20/2016)... -- Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring announced that after exhaustive ... the final acceptance by all three (3) Department ... (MAS) installed. Furthermore, Securus will have contracts for ... October, 2016. MAS distinguishes between legitimate wireless device ...
(Date:6/7/2016)... TORONTO , June 7, 2016  Syngrafii ... begun a business relationship that includes integrating Syngrafii,s ... pilot branch project. This collaboration will result in ... for the credit union, while maintaining existing document ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
Breaking Biology News(10 mins):
(Date:12/5/2016)... -- Research and Markets has announced the addition ... Markets and Companies" to their offering. ... , , ... genome variations, development of sequencing technologies, and their applications. Current ... developing them. Various applications of sequencing are described including those ...
(Date:12/4/2016)... Francisco, CA (PRWEB) , ... December 03, 2016 ... ... grants to ground-breaking microbiome studies. A microbiome impact grant award has been made ... the effect of heavy smoking and drinking on the oral microbiome. Grant proposals ...
(Date:12/2/2016)... ... , ... In anticipation of AxioMed’s exclusive cleanroom manufacturing facility ... Jake Lubinski will be traveling to Switzerland from December 5-10. Mr. Lubinski will ... Zurich to discuss the benefits of a viscoelastic disc. AxioMed received CE mark ...
(Date:12/2/2016)... 2016 Amgen (NASDAQ: AMGN ) and ... submission of a Marketing Authorization Application (MAA) to the European ... Avastin ® (bevacizumab). The companies believe this submission is ... "The submission of ABP 215 to the EMA ... oncology portfolio," said Sean E. Harper , M.D., executive ...
Breaking Biology Technology: